Cooperative Agreement UG3DA061616

The Leland Stanford Junior University, also known as Stanford University, has been awarded a $2,983,510.00 Cooperative Agreement from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support a two-phase research study to assess the effectiveness of deep transcranial magnetic stimulation (dTMS) in modulating neural circuits associated with methamphetamine use disorder and reducing relapse risk.

In the initial UG3 phase, the project will enroll 30 participants with methamphetamine use disorder to determine if the dTMS treatment can effectively engage the targeted neural circuits and result in reduced relapse rates compared to treatment-as-usual. If the UG3 phase milestone criteria are met, the subsequent UH3 phase will then enroll an additional 60 participants in a randomized, double-blind, sham-controlled trial to confirm target engagement and examine the impact of the protocol on methamphetamine use behaviors. The research aims to elucidate the mechanisms of brain and behavior change, accelerate the development of new device-based treatment options, and serve as the basis for a larger-scale clinical trial on new strategies for treating methamphetamine use disorder.